Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter and Six Months ended September 30, 2008
Accounting Standard: International Financial Reporting Standards (IFRS) – First-time adoption period.
Currency: Indian Rupees (Rs.) with convenience translation to U.S. Dollars (U.S.$) at Rs. 46.45 = U.S.$1.00.
DRL is a leading India-based pharmaceutical company operating in Pharmaceutical Services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The company transitioned to IFRS for this reporting period, resulting in significant reconciliations from Previous GAAP.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended Sep 30, 2008 (Rs.) | Six Months Ended Sep 30, 2008 (U.S.$) | Three Months Ended Sep 30, 2008 (Rs.) | Three Months Ended Sep 30, 2008 (U.S.$) |
|---|---|---|---|---|
| Revenue | 31,188,773 | 671,448 | 16,150,970 | 347,706 |
| Gross Profit | 15,457,863 | 332,785 | 7,963,526 | 171,443 |
| Gross Margin % | 49.6% | 49.6% | 49.3% | 49.3% |
| Operating Profit | 2,883,321 | 62,074 | 1,765,511 | 38,009 |
| Net Profit (Period) | 2,163,923 | 46,586 | 1,052,632 | 22,662 |
| EPS (Basic) | Rs. 12.86 | U.S.$ 0.28 | Rs. 6.25 | U.S.$ 0.13 |
| Cash & Equivalents (Sep 30, 2008) | 5,120,446 | 110,236 | - | - |
| Total Debt (Short + Long Term) | 20,705,076 | 445,749 | - | - |
Note: U.S.$ figures are convenience translations. Total Debt includes Short term loans (Rs. 6,190,948), Current portion of long term loans (Rs. 2,545,360), and Long term loans (Rs. 11,968,768).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 27.6% for the six months ended Sep 30, 2008 (Rs. 31.2B vs Rs. 24.4B) and 29.7% for the quarter (Rs. 16.2B vs Rs. 12.5B). Growth was driven by acquisitions (Dow Pharma, BASF Shreveport, Jet Generici) and organic growth in North America, Europe, and Russia.
- Profit Decline: Net profit decreased significantly by 47.5% for the six months (Rs. 2.16B vs Rs. 4.12B) and 58.3% for the quarter (Rs. 1.05B vs Rs. 2.53B). This decline is primarily due to:
- Foreign exchange losses on derivative contracts and translation of foreign currency debt.
- Increased Selling, General, and Administrative (SG&A) expenses (up 29.7% YoY for six months).
- Provisions for legal damages (Eli Lilly olanzapine litigation in Germany).
- One-time tax benefit in the prior year (Sep 2007) due to German tax law changes, which is not recurring.
- Operating Cash Flow: Net cash used in operating activities was Rs. 200.5 million for the six months ended Sep 30, 2008, compared to cash provided of Rs. 2,300.2 million in the prior year. This shift was due to lower profits and increased working capital requirements (inventory build-up and higher receivables).
- Acquisitions: The company completed three major acquisitions in April 2008 (Dow Pharma Unit, BASF Shreveport facility, Jet Generici) and acquired the remaining equity of Perlecan Pharma in July 2008.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Legal Provision: A provision of Rs. 229.6 million was recorded in the quarter ended Sep 30, 2008, regarding probable losses from the Eli Lilly olanzapine patent litigation in Germany. A subsequent event in December 2008 confirmed the loss, leading to further accruals allocated across Q2, Q3, and Q4 2008.
- IFRS Transition: The adoption of IFRS resulted in adjustments to equity and profit, including changes in impairment testing, employee benefit accounting, and hedge accounting.
- Outlook & Strategy:
- Global Generics: Continued focus on the U.S., Germany, India, and Russia. The company launched the authorized generic version of Imitrex in the U.S. and settled patent litigation for desloratidine (Clarinex) with marketing exclusivity starting in 2012.
- Proprietary Products: Launched Promius Pharma in the U.S. to focus on dermatology (launched EpiCeram in Oct 2008). Pipeline includes 2 NCEs in clinical development.
- Germany Market: Facing price pressure due to healthcare reforms (GKV-WSG Act). The company is shifting sourcing to internal networks to reduce costs. A tender process with AOK (German health insurer) was put on hold due to litigation.
- Risks:
- Patent Litigation: Ongoing disputes with Sanofi-Aventis (fexofenadine), Merck (alendronate), and Eli Lilly (olanzapine) pose risks of damages and market bans.
- Regulatory: U.S. FTC investigation into settlement arrangements with UCB Pharma regarding levetiracetam (investigation open but no further requests as of filing).
- Currency: Exposure to foreign exchange volatility, particularly the Indian Rupee vs. U.S. Dollar and Euro.
Investor Verification Checklist
- Legal Provisions: Verify the final settlement amount and impact of the Eli Lilly olanzapine litigation in Germany, as the provision recorded (Rs. 229.6M in Q3) was an estimate subject to change.
- IFRS Impact: Review Note 4 for detailed reconciliations between Previous GAAP and IFRS to understand the true operational performance versus accounting adjustments.
- Working Capital: Monitor the trend in inventory and receivables, as the shift to negative operating cash flow was driven by a significant build-up in these areas.
- Germany Tender: Track the resolution of the AOK tender litigation, as the outcome will impact future revenue visibility in the German market.
- Acquisition Integration: Assess the financial contribution of the Dow Pharma, BASF, and Jet Generici acquisitions against their projected synergies.